GC
MRNA icon

GFG Capital’s Moderna MRNA Stock Holding History

GFG Capital’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-400
Closed -$26.7K – 124
2024
Q3 		$26.7K Hold
400
– – 0.01% 102
2024
Q2 		$47.5K Buy
+400
New +$50.6K 0.01% 124

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

GFG Capital's MRNA Position: Q4 2024 in Review

GFG Capital sold out of Moderna (MRNA) in Q4 2024, closing a stake of 4,740 shares — an estimated $383K sold.

GFG Capital first reported a position in MRNA in Q4 2020 and held it in 16 quarters. The position peaked at $1.07M in Q3 2021. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • GFG Capital reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • GFG Capital sold 4,740 Moderna shares in Q4 2024, an estimated $383K.
  • GFG Capital first reported a position in Moderna in Q4 2020 and held it in 16 quarters.
  • GFG Capital's Moderna position peaked at $1.07M in Q3 2021.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on GFG Capital's 13F filing for Q4 2024, filed 30 Jan 2025.